Nurix Therapeutics stock (US67080M1036): Analyst consensus targets 30.24 USD

Nurix Therapeutics, a clinical-stage biopharmaceutical company, saw its stock close at 16.71 USD on recent trading, reflecting a 24-hour decline of 0.83%, Wallstreet-Online as of May 2026. The shares are down 25.20% from their 52-week high but up 109.74% from the low. Eighteen analysts rate the stock at 4.44 out of 5, with a consensus target of 30.24 USD.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Nurix Therapeutics: core business model

Nurix Therapeutics develops targeted protein degradation technologies for oncology and immune disorders. The company's DELigase platform identifies and advances small molecules degrading disease-causing proteins. Nurix has multiple programs in clinical trials, focusing on degraders for cancer targets like Bruton's tyrosine kinase (BTK).

Key assets include NX-2127 and NX-5948, both BTK degraders in Phase 1b trials for B-cell malignancies. The company partners with Gilead Sciences and others to expand its pipeline. Nurix reported cash reserves supporting operations into 2027, per recent filings.

Main revenue and product drivers for Nurix Therapeutics

Revenue stems from collaboration agreements, with Gilead contributing significantly. In recent quarters, milestone payments and research funding drove top-line growth. The company's protein degradation platform differentiates it in biotech, targeting 'undruggable' proteins.

Pipeline progress, including data readouts from ongoing trials, remains a major catalyst. Monthly performance stood at +2.56% recently, amid biotech sector volatility, Wallstreet-Online as of May 2026.

Industry trends and competitive position

The protein degradation field is heating up, with competitors like Arvinas and Kymera advancing similar tech. Nurix's DELigase E3 ligase screening gives it an edge in molecule optimization. US biotech investors track this space for breakthrough therapies in oncology.

Why Nurix Therapeutics matters for US investors

Listed on Nasdaq, Nurix offers US investors exposure to innovative biotech without overseas risks. Its focus on immuno-oncology aligns with major US healthcare spending trends, making it relevant amid rising demand for targeted cancer treatments.

Conclusion

Nurix Therapeutics continues advancing its degradation platform with promising clinical data and strong analyst support targeting above current levels. Shares show volatility typical of clinical biotech, with recent trading at 16.71 USD. Investors monitor upcoming trial results for potential catalysts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.